Cargando…
O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426851/ http://dx.doi.org/10.1097/01.HS9.0000872820.66998.56 |
| _version_ | 1784778771632488448 |
|---|---|
| author | M., TELEN R., BROWN R., HAGAR M., IDOWU I., OSUNKWO T., KALFA F., KUYPERS J., GEIB P., SCHROEDER E., WU P., KELLY S., SARAF |
| author_facet | M., TELEN R., BROWN R., HAGAR M., IDOWU I., OSUNKWO T., KALFA F., KUYPERS J., GEIB P., SCHROEDER E., WU P., KELLY S., SARAF |
| author_sort | M., TELEN |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9426851 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94268512022-08-31 O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH M., TELEN R., BROWN R., HAGAR M., IDOWU I., OSUNKWO T., KALFA F., KUYPERS J., GEIB P., SCHROEDER E., WU P., KELLY S., SARAF Hemasphere Oral Presentations Lippincott Williams & Wilkins 2022-08-16 /pmc/articles/PMC9426851/ http://dx.doi.org/10.1097/01.HS9.0000872820.66998.56 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Presentations M., TELEN R., BROWN R., HAGAR M., IDOWU I., OSUNKWO T., KALFA F., KUYPERS J., GEIB P., SCHROEDER E., WU P., KELLY S., SARAF O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title | O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_full | O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_fullStr | O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_full_unstemmed | O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_short | O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH |
| title_sort | o-03: etavopivat treatment for up to 12 weeks in patients with sickle cell disease is well tolerated and improves red blood cell health |
| topic | Oral Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426851/ http://dx.doi.org/10.1097/01.HS9.0000872820.66998.56 |
| work_keys_str_mv | AT mtelen o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT rbrown o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT rhagar o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT midowu o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT iosunkwo o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT tkalfa o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT fkuypers o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT jgeib o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT pschroeder o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT ewu o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT pkelly o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth AT ssaraf o03etavopivattreatmentforupto12weeksinpatientswithsicklecelldiseaseiswelltoleratedandimprovesredbloodcellhealth |